Seasonal Allergic Rhinitis
📧 Sign up to get email alerts when something new happens for Seasonal Allergic Rhinitis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2016-05-30Clinical Trial Update: Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Seasonal Allergic Rhinitis (MK-4117-204) [Phase 3]
A Phase 3 trial update reports efficacy and safety results for desloratadine (MK-4117) in Japanese participants with Seasonal Allergic Rhini…
-
CLINICAL_TRIALS trial_result · 2016-05-23Clinical Trial Update: Efficacy and Safety of Sublingual Tablets of Grass Pollen Allergen Extract [Phase 1]
Phase 1 clinical trial evaluating the safety and efficacy of sublingual grass pollen allergen extract tablets for seasonal allergic rhinitis…
-
CLINICAL_TRIALS safety_alert · 2016-05-16Clinical Trial Update: Post Marketing Surveillance for Contac Bien Z in Japan
Post-marketing safety surveillance for Contac Bien Z in Japan has been completed. The surveillance evaluated safety in patients with allergi…
-
FDA approval · 2016-04-19FDA Approved: MONTELUKAST SODIUM — Supplemental Application (Unichem Pharmaceuticals (USA), Inc.)
FDA approved a supplemental application for Montelukast Sodium from Unichem Pharmaceuticals (USA), Inc., under the ANDA.
-
CLINICAL_TRIALS trial_result · 2016-04-11Clinical Trial Update: Efficacy and Safety of SPARC1310 in Seasonal Allergic Rhinitis [Phase 2]
Phase 2 trial results for SPARC1310 in seasonal allergic rhinitis have been completed and results posted.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2016-03-17FDA Approved: OMNARIS — Supplemental Application (Covis Pharma US, Inc)
FDA approved a supplemental application for Omnaris (ciclesonide) submitted by Covis Pharma US, Inc. The notice indicates the supplemental a…
-
FDA approval · 2016-01-26FDA Approved: FEXOFENADINE HCL AND PSEUDOEPHEDRINE HCI — Supplemental Application (Dr. Reddy's Laboratories Inc.)
FDA approved a supplemental application for a fixed-dose combination of fexofenadine HCl and pseudoephedrine HCl to treat allergy symptoms w…
-
FDA approval · 2016-01-26FDA Approved: FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE — Supplemental Application (AmeriSource Bergen)
FDA approved a supplemental application for the combination product fexofenadine hydrochloride and pseudoephedrine hydrochloride (AmeriSourc…
-
CLINICAL_TRIALS trial_result · 2016-01-18Clinical Trial Update: Safety Study of MK-3641 and MK-7243 Co-administered in Adult Participants With Ragweed and Grass Pollen Induced Allergic Rhinitis (P08607, MK-3641-006) [Phase 4]
This clinical trial update reports the results of a Phase 4 safety study evaluating co-administration of MK-3641 and MK-7243 in adults with …
-
FDA approval · 2016-01-12FDA Approved: MONTELUKAST SODIUM — Original Application (Westminster Pharmaceuticals, LLC)
FDA approved Westminster Pharmaceuticals, LLC's original application for Montelukast SODIUM, establishing a generic montelukast sodium produ…
-
FDA approval · 2016-01-04FDA Approved: MONTELUKAST SODIUM — Supplemental Application (Torrent Pharmaceuticals Limited)
FDA approved a supplemental application for Montelukast Sodium from Torrent Pharmaceuticals Limited. The entry indicates a supplemental appr…
-
CLINICAL_TRIALS trial_result · 2015-12-22Clinical Trial Update: MK0524 Seasonal Allergic Rhinitis Study (0524-005)(COMPLETED) [Phase 2]
This record notes the completion of Merck's Phase 2 MK0524 trial for seasonal allergic rhinitis (NCT00533208).
-
CLINICAL_TRIALS trial_result · 2015-12-08Clinical Trial Update: Study Immunology and Safety of 60-day Treatment of SQ Grass SLIT (Sublingual Immunotherapy)-Tablet in Adult Subjects With Grass Pollen-induced Allergic Rhinoconjunctivitis [Phase 3]
Completed Phase 3 trial evaluating the immunology and safety of a 60-day course of SQ Grass SLIT-Tablet in adults with grass pollen–induced …
-
FDA approval · 2015-11-25FDA Approved: CLARITIN-D 12 HOUR — Supplemental Application (Bayer HealthCare LLC.)
FDA approved a supplemental application for Claritin-D 12 Hour, combining loratadine and pseudoephedrine sulfate. The approval expands the p…
-
CLINICAL_TRIALS trial_result · 2015-11-02Clinical Trial Update: Study of the Effect of SCH 900538 on Congestion in Subjects With Seasonal Allergic Rhinitis (Study P05031)(COMPLETED) [Phase 2]
A Phase 2 clinical trial (Study P05031) evaluating SCH 900538 for congestion in seasonal allergic rhinitis has completed.
-
CLINICAL_TRIALS trial_result · 2015-11-02Clinical Trial Update: Study to Compare the Therapeutic Equivalence of Mometasone Furoate Nasal Spray, 50 mcg With Nasonex Nasal Spray in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis [Phase 3]
A Phase 3 trial comparing the therapeutic equivalence of a mometasone furoate nasal spray (50 mcg) with Nasonex nasal spray for seasonal all…
-
FDA approval · 2015-10-16FDA Approved: CLARINEX-D 12 HOUR — Supplemental Application (Organon LLC)
FDA approved a supplemental application for CLARINEX-D 12 HOUR, a desloratadine and pseudoephedrine sulfate combination, from Organon LLC.
-
CLINICAL_TRIALS trial_result · 2015-10-12Clinical Trial Update: A Study of Epinastine Nasal Spray in Subjects With Seasonal Allergic Rhinitis [Phase 2]
Phase 2 trial evaluating epinastine nasal spray for Seasonal Allergic Rhinitis has completed. The study assessed safety and efficacy in affe…
-
FDA approval · 2015-10-08FDA Approved: MONTELUKAST SODIUM — Original Application (Unichem Pharmaceuticals (USA), Inc.)
FDA approved Unichem Pharmaceuticals (USA), Inc.'s Montelukast Sodium generic under Original Application (ANDA204290), authorizing its marke…
-
FDA approval · 2015-10-01FDA Approved: LEVOCETIRIZINE DIHYDROCHLORIDE — Supplemental Application (Marlex Pharmaceuticals Inc)
FDA approved a supplemental application for levocetirizine dihydrochloride from Marlex Pharmaceuticals Inc, indicating an approved regulator…
-
FDA approval · 2015-09-25FDA Approved: MONTELUKAST SODIUM — Supplemental Application (Macleods Pharmaceuticals Limited)
FDA approved a supplemental application for Montelukast Sodium submitted by Macleods Pharmaceuticals Limited.
-
CLINICAL_TRIALS research · 2015-09-23Clinical Trial Update: 4"S" - Seasonal Symptoms Suppression Study [Phase 4]
A Phase 4 clinical trial update for seasonal allergic rhinitis conducted by Association Asthma in Bulgaria. The current status of the study …
-
CLINICAL_TRIALS trial_result · 2015-08-14Clinical Trial Update: Tolerability/Safety of Intranasal AZD8848 in Healthy Male Volunteers and Seasonal Allergic Rhinitis Male Patients Out of Season [Phase 1]
This Phase 1 study assessed the tolerability and safety of intranasal AZD8848 in healthy male volunteers and in male patients with seasonal …
-
FDA approval · 2015-07-31FDA Approved: MONTELUKAST SODIUM — Original Application (Ajanta Pharma USA Inc.)
FDA approved Montelukast Sodium as an original application generic product for Ajanta Pharma USA Inc.
-
FDA approval · 2015-07-31FDA Approved: MONTELUKAST SODIUM — Original Application (Ajanta Pharma USA Inc.)
FDA approved Ajanta Pharma USA Inc.'s original application for montelukast sodium (generic montelukast), authorizing a generic product for t…